RECRUITING

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Conditions

Non-Hodgkin Lymphoma Burkitt Lymphoma Diffuse Large B-Cell Lymphoma Primary Mediastinal B-cell Lymphoma CD20+ Lymphoblastic Lymphoma Follicular Lymphoma, Grade III

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).

Official Title

Chemoimmunotherapy With Obinutuzumab, Ifosfamide, Carboplatin and Etoposide (O-ICE) in Children, Adolescents and Young Adults With Recurrent Refractory CD20+ Mature B-NHL

Quick Facts

Study Start:2015-08-21

Study Completion:2024-12

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT02393157

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:3 Years to 31 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:CHILD, ADULT

Inclusion Criteria	Exclusion Criteria
* Patients in first relapse or primary induction failure CD20 positive B-cell leukemia/lymphoma including: * Diffuse Large B-Cell Lymphoma * Burkitt Lymphoma * High Grade B-cell Lymphoma: Not Otherwise Specified (NOS) * Primary mediastinal B-cell lymphoma (PMBL) * CD20+ B-lymphoblastic lymphoma * Follicular lymphoma, Grade III * Karnofsky ≥ 60% for patients \> 16 years of age and * Lansky ≥ 60 for patients ≤ 16 years of age. * Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study. * Patients may not have received prior therapy with obinutuzumab (GA101) * Radiation Therapy (XRT): Date of receiving prior XRT must be \> 2 weeks for local palliative XRT (small port); \> 6 months must have elapsed if prior craniospinal XRT or if \> 50% radiation of pelvis; \> 6 weeks must have elapsed if other substantial bone marrow radiation. * Steroids: Patients may have received prior steroid treatment, but not started greater than 7 days prior to initiation of protocol therapy. * Adequate organ function.	* Patients with newly diagnosed, previously untreated B-NHL. * Known congenital or acquired immune deficiency. * Prior solid organ transplantation. * Prior allogeneic stem cell transplant within 60 days or active acute Graft-vs-Host-Disease (GVHD) grade 3 or higher. * History of grade 4 anaphylactic reactions to humanized or murine monoclonal antibodies * Uncontrolled hepatitis B and/or C infection

Inclusion Criteria

Exclusion Criteria

* Patients in first relapse or primary induction failure CD20 positive B-cell leukemia/lymphoma including:
* Diffuse Large B-Cell Lymphoma
* Burkitt Lymphoma
* High Grade B-cell Lymphoma: Not Otherwise Specified (NOS)
* Primary mediastinal B-cell lymphoma (PMBL)
* CD20+ B-lymphoblastic lymphoma
* Follicular lymphoma, Grade III
* Karnofsky ≥ 60% for patients \> 16 years of age and
* Lansky ≥ 60 for patients ≤ 16 years of age.
* Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study.
* Patients may not have received prior therapy with obinutuzumab (GA101)
* Radiation Therapy (XRT): Date of receiving prior XRT must be \> 2 weeks for local palliative XRT (small port); \> 6 months must have elapsed if prior craniospinal XRT or if \> 50% radiation of pelvis; \> 6 weeks must have elapsed if other substantial bone marrow radiation.
* Steroids: Patients may have received prior steroid treatment, but not started greater than 7 days prior to initiation of protocol therapy.
* Adequate organ function.

* Patients with newly diagnosed, previously untreated B-NHL.
* Known congenital or acquired immune deficiency.
* Prior solid organ transplantation.
* Prior allogeneic stem cell transplant within 60 days or active acute Graft-vs-Host-Disease (GVHD) grade 3 or higher.
* History of grade 4 anaphylactic reactions to humanized or murine monoclonal antibodies
* Uncontrolled hepatitis B and/or C infection

Contacts and Locations

Study Contact

Mitchell Cairo, MD

CONTACT

914-594-2150

Mitchell_Cairo@nymc.edu

Jessica Hochberg, MD

CONTACT

914-594-2150

jessica_hochberg@nymc.edu

Principal Investigator

Mitchell Cairo, MD

STUDY_CHAIR

New York Medical College

Matthew Barth, MD

PRINCIPAL_INVESTIGATOR

Roswell Park Cancer Institute

Study Locations (Sites)

New York Medical College

Valhalla, New York, 10595

United States

Collaborators and Investigators

Sponsor: New York Medical College

Mitchell Cairo, MD, STUDY_CHAIR, New York Medical College
Matthew Barth, MD, PRINCIPAL_INVESTIGATOR, Roswell Park Cancer Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2015-08-21

Study Completion Date2024-12

Study Record Updates

Study Start Date2015-08-21

Study Completion Date2024-12

Terms related to this study

Additional Relevant MeSH Terms

Non-Hodgkin Lymphoma
Burkitt Lymphoma
Diffuse Large B-Cell Lymphoma
Primary Mediastinal B-cell Lymphoma
CD20+ Lymphoblastic Lymphoma
Follicular Lymphoma, Grade III